Abstract: The present invention discloses an anti-giant panda LIF monoclonal antibody, a hybridoma cell line, and use thereof, and belongs to the field of biotechnology. The antibody comprises a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO. 1 and a light chain variable region having an amino acid sequence set forth in SEQ ID NO. 2. The hybridoma cell line LIF-2 is deposited at China Center for Type Culture Collection on Oct. 28, 2021 with the accession number of CCTCC NO: C202171. The anti-giant panda LIF monoclonal antibody developed by the present invention can accurately identify the target protein LIF, and lays an important foundation for LIF protein localization, tissue expression information, study on LIF and a receptor and a target cell thereof by using the high-specificity LIF monoclonal antibody and exploration of the effect of LIF in embryonic diapause in giant pandas.

Abstract: The present disclosure relates to media compositions and/or supplements to be added into an organoid medium, and to methods for generating apical-out organoids. Apical-out organoids exhibit an apical surface thereof facing the external environment, and an inwardly disposed basolateral surface. Apical-out organoids may be formed in organoid media comprise a basal medium and one or more of an inhibitor of notch signaling and an inhibitor of signaling through a TGF. Apical-out organoids formed in accordance with the disclosed methods or in the disclosed media may be used to assay host responses to pathogens.

Abstract: The present disclosure provides an electronic device and a modulation method. The electronic device includes: a receiving unit, which is configured to obtain a first input bit sequence; and a control unit, which is configured to perform pseudo N-order first type modulation on the first input bit sequence, wherein N first symbols that may be obtained by means of the pseudo N-order first type modulation are a portion of second symbols that may be obtained by means of M-order second type modulation, M and N are positive integers, and M is greater than N.

Abstract: The present disclosure provides electronic equipment. The electronic equipment includes: an input unit, configured to: determine a sequence to be compressed based on a data sequence, a head sequence and a tail sequence, wherein the sequence to be compressed has Q elements, and Q is an integer greater than 0; a processing unit, configured to: determine, based on the sequence to be compressed, a DFT spreading sequence by utilizing DFT spreading, and perform at least one of data deleting operation or data superposing operation on the DFT spreading sequence to determine a compressed sequence, wherein the compressed sequence has M symbols, M is an integer greater than 0, and M is less than Q.

Abstract: The present invention provides a stent and a drug-loaded stent. The stent includes at least one stent mesh, wherein each stent mesh comprises a plurality of stent struts sequentially connected circumferentially around the stent mesh, wherein the plurality of the stent struts are sequentially connected end to end, and a joint is formed at the connected ends of adjacent stent struts. The stent mesh is configured to expand or collapse as a result of widening or narrowing of angles at the joints. Each stent strut includes at least one main section and at least one broadened section. The main section has a width smaller than that of the broadened section. In each stent mesh, the broadened sections of adjacent stent struts are staggered along an axis of the stent mesh. The drug-loaded stent is of a similar structure.

Abstract: A stent and a drug-loaded stent, each including at least one stent mesh, each stent mesh includes a plurality of stent struts, which are connected end to end circumferentially around the stent mesh, and a joint is formed at the connected ends of adjacent stent struts. The stent mesh is configured to expand or collapse as a result of widening or narrowing of angles at the joints. Each stent strut includes at least one main section and at least one broadened section. The main section has a width smaller than that of the broadened section. In each stent mesh, the broadened sections of adjacent stent struts are staggered along an axis of the stent mesh. This arrangement enables reasonable space utilization and achieves a good tradeoff between metal coverage and radial strength of the stent.

Abstract: A stent and a drug-loaded stent. The stent includes at least one stent mesh each including a plurality of stent struts, which are connected end to end circumferentially around the stent mesh, a joint is formed at the connected ends of adjacent stent struts. The stent mesh is configured to expand or collapse as a result of widening or narrowing of angles at the joints. Each stent strut includes at least one main section and at least one broadened section. The main section has a width smaller than that of the broadened section. In each stent mesh, the broadened sections of adjacent stent struts are staggered along an axis of the stent mesh. The different widths of the broadened sections and the main sections, as well as the staggered arrangement of the broadened sections, enable reasonable space utilization and achieve a good tradeoff between metal coverage and radial strength of the stent.

Abstract: A terminal determines a target code rate by using a reference code rate, which is based on a modulation scheme and a modulation order, and an adjustment coefficient ? that lowers the reference code rate. The terminal transmits/receives a signal encoded based on the target code rate.

Abstract: The present disclosure provides an electronic device, including: an input unit configured to obtain a sequence to be compressed, wherein the sequence to be compressed has Q time-domain symbol elements, and Q is an integer greater than zero; a processing unit configured to perform a zero-padding operation on the sequence to be compressed according to at least a part of a compression factor to determine a zero-embedded sequence, perform a discrete Fourier transform spreading operation according to the zero-embedded sequence to determine a spread sequence, and perform at least one of a data deletion operation and a data superimposition operation based on the spread sequence to determine a compressed sequence, wherein the compressed sequence has M frequency-domain symbols, M is an integer greater than zero, and M is less than or equal to Q.

Abstract: A radiopaque structure, a stent and a thrombectomy system are disclosed. The radiopaque structure includes: at least one protrusion each for securing, supporting and connecting a radiopaque sleeve (2); at least one radiopaque sleeve (2) disposed over the respective at least one protrusion; and at least one filler (3) filled in a gap between the radiopaque sleeve (2) and the protrusion. Compared with the prior art, the radiopaque mechanism can enhance fluoroscopic visibility of radiopaque dots disposed at a distal end of a laser-cut thrombectomy device and solves the problem that not all metal struts in the laser-cut thrombectomy device can be seen under fluoroscopic imaging. The radiopaque structure can be used in any types of stent and is not limited to being used in a thrombectomy device.

Abstract: The present invention relates to a delivery guidewire and a therapeutic treatment device including the delivery guidewire. The delivery guidewire includes a core shaft and a driving member arranged on the core shaft, and the driving member includes inner and outer components. The inner component is made of a metal and fixedly sleeved over the core shaft, and the outer component is made of a polymeric material and fixedly sleeved over the inner component. The inner component fixedly sleeved over the core shaft indirectly enhances attachment of the outer component to the core shaft, thus reducing the risk of loosening, wrinkling or displacement of the outer component and resulting in improved safety and reliability of the delivery guidewire during use.

Abstract: Described are devices for tethering biological materials, which in applicable embodiments support the growth and differentiation thereof. In a specific embodiment, the biological materials are cells and the cells grow/differentiate into tethered three-dimensional aggregates. The devices disclosed herein may be used in various methods/assays relating to tethered biological materials, such as to tethered three-dimensional aggregates of cells.

Abstract: A delivery guide wire (10,100) and a therapeutic device are disclosed. The therapeutic device includes the delivery guide wire (10, 100), a medical implant and a delivery catheter (20). The delivery guide wire (10, 100) includes a core shaft (110) and a driving member (120) disposed on the core shaft (110), and the driving member (120) defines thereon a depression. The medical implant is compressed by the delivery catheter (20) and disposed over the delivery guide wire (10,100) in such a manner that it is at least partially received in the depression. This results in an increased contact area between the medical implant and the delivery guide wire (10, 100), which facilitates movement of the medical implant in sync with the delivery guide wire (10, 100) and makes its delivery easier.

Abstract: A biodegradable cross-linked polymer and methods of preparing same are provided. The biodegradable cross-linked polymer is formed from a biodegradable polymeric material having two or more arms, which is a random copolymer formed of a first monomer and a second monomer different from the first monomer. The first monomer is selected from the group consisting of L-lactide, DL-lactide, glycolid, ?-caprolactone, trimethylene carbonate, p-dioxanone, amino acid-derived polycarbonates and polyorthoesters. The second monomer is one or two selected from the group consisting of D-lactide, DL-lactide, glycolide, ?-caprolactone, trimethyl carbonate, salicylic acid, carbonates, amino acids and derivatives thereof. The biodegradable polymeric material has a molecular weight of from 5,000 to 1,200,000 and an intrinsic viscosity of from 0.1 to 9.0 dl/g. Each of the terminal groups on the arms of the biodegradable polymeric material is selected from the group consisting of hydroxyl amino and carboxyl groups.

Abstract: A biodegradable cross-linked polymer and methods of preparing same are provided. The biodegradable cross-linked polymer is formed from a biodegradable polymeric material having two or more arms, which is a random copolymer formed of a first monomer and a second monomer different from the first monomer. The first monomer is selected from the group consisting of L-lactide, DL-lactide, glycolid, ?-caprolactone, trimethylene carbonate, p-dioxanone, amino acid-derived polycarbonates and polyorthoesters. The second monomer is one or two selected from the group consisting of D-lactide, DL-lactide, glycolide, ?-caprolactone, trimethyl carbonate, salicylic acid, carbonates, amino acids and derivatives thereof. The biodegradable polymeric material has a molecular weight of from 5,000 to 1,200,000 and an intrinsic viscosity of from 0.1 to 9.0 dl/g. Each of the terminal groups on the arms of the biodegradable polymeric material is selected from the group consisting of hydroxyl amino and carboxyl groups.

Abstract: The present invention relates to the field of medical instruments. Specifically, a biodegradable cross-linked polymer and a manufacturing method therefor are provided. The cross-linked polymer is obtained by bonding crosslinkable reactive groups to terminal groups of a biodegradable prepolymer having two or more arms and further subjecting the prepolymer to thermal polymerization and/or light irradiation. The cross-linked polymer has an elastic modulus of 10-4,500 MPa, and a degradation rate of 3-36 months. A biodegradable vascular stent and a preparation method therefor are also provided. The vascular stent is formed by laser cutting of polymeric tubing having a three-dimensional cross-linked network structure. The vascular stent has ample mechanical strength, a high elastic modulus at body temperature, and a regulatable degradation rate.

Abstract: The present invention relates to the field of medical instruments. Specifically, a biodegradable cross-linked polymer and a manufacturing method therefor are provided. The cross-linked polymer is obtained by bonding crosslinkable reactive groups to terminal groups of a biodegradable prepolymer having two or more arms and further subjecting the prepolymer to thermal polymerization and/or light irradiation. The cross-linked polymer has an elastic modulus of 10-4,500 MPa, and a degradation rate of 3-36 months. A biodegradable vascular stent and a preparation method therefor are also provided. The vascular stent is formed by laser cutting of polymeric tubing having a three-dimensional cross-linked network structure. The vascular stent has ample mechanical strength, a high elastic modulus at body temperature, and a regulatable degradation rate.